SpliceBio vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AAV cargo limit.
About
SpliceBio is a gene therapy company whose protein trans-splicing platform overcomes the 4.7-kilobase cargo limit of adeno-associated viral (AAV) vectors — the primary delivery vehicle for gene therapy — unlocking treatments for large-gene diseases previously untreatable. The company raised $135 million in Series B financing co-led by Sanofi Ventures and EQT Life Sciences in June 2025, and dosed its first patient in Phase 1/2 Part B for SB-007 in Stargardt disease in January 2026.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.